Analysts Offer Insights on Healthcare Companies: S
Post# of 81
(Total Views: 510)
Posted On: 09/14/2017 8:48:03 AM
Analysts Offer Insights on Healthcare Companies: Soleno Therapeutics Inc (NASDAQ: SLNO) and Alexion Pharmaceuticals (NASDAQ: ALXN)
http://www.analystratings.com/articles/analys...ore-502551
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Soleno Therapeutics Inc (NASDAQ: SLNO) and Alexion Pharmaceuticals (NASDAQ: ALXN) with bullish sentiments.
Soleno Therapeutics Inc (NASDAQ: SLNO)
Maxim Group analyst Gabrielle Zhou assigned a Buy rating to Soleno Therapeutics Inc (NASDAQ: SLNO) today and set a price target of $5. The company’s shares opened today at $0.62.
Zhou noted:
“Soleno today announced the issuance of a new patent (9,757,384) from the U.S. Patent and Trademark Office for the use of pharmaceutical formulations of diazoxide and diazaxide choline (Diazoxide Choline Controlled Release Tablet; DCCR) to reduce aggressive behaviors in patients with Prader-Willi syndrome (PWS) or Smith-Magenis syndrome (SMS).”
http://www.analystratings.com/articles/analys...ore-502551
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Soleno Therapeutics Inc (NASDAQ: SLNO) and Alexion Pharmaceuticals (NASDAQ: ALXN) with bullish sentiments.
Soleno Therapeutics Inc (NASDAQ: SLNO)
Maxim Group analyst Gabrielle Zhou assigned a Buy rating to Soleno Therapeutics Inc (NASDAQ: SLNO) today and set a price target of $5. The company’s shares opened today at $0.62.
Zhou noted:
“Soleno today announced the issuance of a new patent (9,757,384) from the U.S. Patent and Trademark Office for the use of pharmaceutical formulations of diazoxide and diazaxide choline (Diazoxide Choline Controlled Release Tablet; DCCR) to reduce aggressive behaviors in patients with Prader-Willi syndrome (PWS) or Smith-Magenis syndrome (SMS).”
(0)
(0)Soleno Therapeutics, Inc. (SLNO) Stock Research Links
Scroll down for more posts ▼